Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Common Equity: 2016-2024

Historic Common Equity for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $228.8 million.

  • Collegium Pharmaceutical's Common Equity rose 17.30% to $274.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.8 million, marking a year-over-year increase of 17.30%. This contributed to the annual value of $228.8 million for FY2024, which is 17.10% up from last year.
  • Collegium Pharmaceutical's Common Equity amounted to $228.8 million in FY2024, which was up 17.10% from $195.4 million recorded in FY2023.
  • Collegium Pharmaceutical's Common Equity's 5-year high stood at $228.8 million during FY2024, with a 5-year trough of $186.0 million in FY2020.
  • Over the past 3 years, Collegium Pharmaceutical's median Common Equity value was $195.4 million (recorded in 2023), while the average stood at $206.4 million.
  • Per our database at Business Quant, Collegium Pharmaceutical's Common Equity surged by 112.77% in 2020 and then fell by 3.98% in 2022.
  • Collegium Pharmaceutical's Common Equity (Yearly) stood at $186.0 million in 2020, then rose by 9.08% to $202.9 million in 2021, then declined by 3.98% to $194.8 million in 2022, then climbed by 0.30% to $195.4 million in 2023, then rose by 17.10% to $228.8 million in 2024.